A non-interventional prospective study of 1-st line treatment approaches in OVArian cancer patients with HRD+ status in Russian Federation

Trial Identifier: D133FR00195
Sponsor: AstraZeneca
Start Date: June 2023
Primary Completion Date: July 2025
Study Completion Date: July 2025
Condition: Ovarian Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Russia Arkhangelsk, Russia
Russia Barnaul, Russia
Russia Chelyabinsk, Russia
Russia Grozniy, Russia
Russia Irkutsk, Russia
Russia Izhevsk, Russia
Russia Kaliningrad, Russia
Russia Kaluga, Russia
Russia Krasnodar, Russia
Russia Krasnoyarsk, Russia
Russia Lyubertcy, Russia
Russia Moscow, Russia
Russia N.Novgorod, Russia
Russia Nalchik, Russia
Russia Novosibirsk, Russia
Russia Omsk, Russia
Russia Saratov, Russia
Russia Sochi, Russia
Russia St.Petersburg, Russia
Russia Tomsk, Russia
Russia Ufa, Russia
Russia Vladivostok, Russia
Russia Yakutiya, Russia
Russia Yaroslavl, Russia